
The study assessed the impact of portal hypertension on liver injury in cirrhosis by analyzing m30 and m65 cell death markers in patients undergoing TIPS for refractory ascites. Results indicated higher baseline levels of m30 and m65 in decompensated cirrhosis, which decreased post-TIPS to levels comparable with compensated cirrhosis. Baseline m30/m65 levels did not predict six-month survival, implying TIPS may mitigate adverse outcomes despite elevated marker levels. Findings underscore TIPS as a key intervention to reduce liver cell death and improve prognosis in decompensated cirrhosis.
Like
Save
Share